Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18587031 | 0.90 | CA2 (0.59) | CA2CA1CA12CA7CA14 | |
| SCHEMBL968326 | 0.86 | PKM (0.57) | CA2CA1CA12CA7CA14 | |
| SCHEMBL3063829 | 0.82 | KAT6A (0.48) | CA2CA1CA12CA7CA14 | |
| SCHEMBL2530001 | 0.82 | KAT6A (0.45) | KAT6ACHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL8164694 | 0.82 | CHRM2 (0.48) | PNMTKAT6ACHRM2CHRM1CHRNB2 | |
| SCHEMBL2549992 | 0.79 | PKM (0.61) | CA2CA12CA9PKMPTGS1 | |
| SCHEMBL15381300 | 0.78 | KAT6A (0.51) | PNMTKAT6ACHRM2CHRM1CHRNB2 | |
| SCHEMBL19718854 | 0.78 | CHRM2 (0.45) | KAT6ACHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL12989734 | 0.76 | CA12 (0.56) | CA2CA12CA9PKMPTGS1 | |
| SCHEMBL6674134 | 0.76 | CA2 (0.59) | CA2CA1CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2010002802-A1 | PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-0583960-B1 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | LILLY CO ELI (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5387681-A | Reacting a bicyclic aromatic compound with a complex of sulfur trioxide-N,N-dimethylformamide; water miscible, non-reactive solvent; thionyl halide | ELI LILLY AND COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
| EP-0583960-A2 | Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides | ELI LILLY AND COMPANY (US) | 1994-02-23 | — | — | EP | disclosed |
| EP-0254577-B1 | SYNTHESIS OF BICYCLIC AROMATIC SULFONYL CHLORIDES | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0254577-A1 | Synthesis of bicyclic aromatic sulfonyl chlorides | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CA2 294/4885CA1 1974/4885CA12 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.